Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822701 · ClinicalTrials.gov registry record · Phase 2
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04822701 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 5 participants.
The verdict
NCT04822701, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is open to adults with mild to moderate symptoms of COVID-19 (coronavirus disease). The purpose of this study is to find out whether a medicine called BI 767551 helps people with COVID-19. BI 767551 is an antibody against the coronavirus. The study has 2 parts. Part 1 wants to find out the best dose of BI 767551 given as infusion into a vein. It also tests how BI 767551 is taken up by the body when taken via an inhaler. Participants are put into 4 groups by chance. Participants get BI 767551 or placebo once. * 1 group gets a high dose of BI 767551 as an infusion into a vein * 1 group gets a low dose of BI 767551 as an infusion into a vein * 1 group gets BI 767551 via an inhaler * 1 group gets placebo both as an infusion into a vein and via an inhaler The placebo infusion and inhaler look like the BI 767551 infusion and inhaler but do not contain any medicine. Doctors check how BI 767551 reduces the amount of coronavirus. Once the best dose of BI 767551 is found, part 2 of the study tests BI 767551 in a larger group of people. Also, in part 2, the participants get BI 767551 or placebo as an infusion into a vein once. In this part, doctors will check how many people need to be treated in a hospital or die. The results will be compared between the groups. For each part, participants are in the study for about 13 weeks. During this time, they visit the study site about 8 times and get about 3 remote visits. The doctors also regularly check participants' health and take note of any unwanted effects of BI 767551.
Interventions
- DRUG BI 767551 intravenous
- DRUG BI 767551 inhaled
- DRUG Placebo intravenous
- DRUG Placebo inhaled
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2021-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04822701
The ClinicalTrials.gov registry entry for NCT04822701 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BI 767551 intravenous is the first listed.
NCT04822701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04822701 about?
NCT04822701 is a clinical study titled "A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19". This study is open to adults with mild to moderate symptoms of COVID-19 (coronavirus disease). The purpose of this study is to find out whether a medicine called BI 767551 helps people with COVID-19. BI 767551 is an antibody against the coronavirus. The study has 2 parts. Part 1 wants to find out ...
What is the current status of trial NCT04822701?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-04-21. Estimated completion is 2021-10-04.
What interventions are being tested in trial NCT04822701?
The interventions under investigation include: BI 767551 intravenous (DRUG), BI 767551 inhaled (DRUG), Placebo intravenous (DRUG), Placebo inhaled (DRUG).
Who is sponsoring clinical trial NCT04822701?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.